XS-228

N/A

Report date: 2025/08/13 17:32:16

Base Information

Drug NameXS-228
Drug Alias NameHuman Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells therapy (XellSmart Bio-Pharmaceutical)XS228XS-228XS228CN
ClassificationCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Somatic cell > Motor neuron progenitor cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsRejection of organ transplantationSpinal Cord InjuriesAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXellSmart Bio-Pharmaceutical (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXellSmart Bio-Pharmaceutical (Suzhou) Co LtdXellSmart Bio-Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationSpinal Cord InjuriesAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A